FGFR1 and HER1 or HER2 co‑amplification in breast cancer indicate poor prognosis

Abstract

Human epidermal growth factor receptor 1 or 2 (HER1/2), and fibroblast growth factor receptor 1 (FGFR1) signaling serve critical roles in the progression of breast cancer; however, cross-talk between HER1/2 and FGFR1 signaling has not been extensively studied. In the present study, the copy number variation status of FGFR1 and HER1/2, and the clinical implications and prognostic relevance of this, were evaluated in invasive ductal breast cancer (IDC) tissue samples. Quantitative polymerase chain reaction and fluorescence in situ hybridization were used to assess gene copy number variation in IDC samples, and the clinical characteristics and survival curves of patients with IDC were analyzed. The amplification of FGFR1 was identified in 16.0% of the samples (12 of 75), of HER1 in 26.7% (20 of 75), of HER2 in 37.3% (28 of 75), and of FGFR1 and HER1/2 simultaneously in 8.0% (6 of 75). FGFR1 and HER1/2 co-amplification were significantly correlated with distant metastasis (P=0.035), recurrence (P=0.026) and decreased disease-free survival time (P=0.042). This was the case for patients undergoing endocrine therapy (P=0.002) and chemotherapy (P=0.044). Taken together, the results indicate that patients with FGFR1 and HER1/2 co-amplification may exhibit a less favorable prognosis compared with patients with either FGFR1, HER1/2 amplification or without amplification.

Clinical Implications of Sub-grouping HER2 Positive Tumors by Amplicon Structure and Co-amplified Genes

“…In other tumors, a TR of ERBB2 segment linked by an inversion to 17q21.3 was associated with a BRCA1 loss, leading to a DM structure 16 . In HER2+ breast cancer patients co-amplification of EGFR 17 , FGFR1 18 and MYC 19 is a poor prognostic marker.…”

FGFR aberrations increase the risk of brain metastases and predict poor prognosis in metastatic breast cancer patients

“…35,36 In HER2-positive BCs, the co-amplification of FGFR1, ERBB1, and ERBB2 results in a worse prognosis compared with patients with individual amplification or without amplification. 45 In this study, among 22 detected FGFR-aberrant patients, 16 were HR-positive MBC patients (14 were HR+/ HER2-and 2 were HR+/HER2+), 5 were TNBC and 1 was HR-/HER2+ ( 5). Some patients with these nonpathogenic mutations had poor response to anti-cancer treatment, so in future we need to focus on the function of these mutations.…”

Screening and Identification of Key Biomarkers in Gastric Cancer: Three Genes Jointly Predict Gastric Cancer

“…HER2 is encoded by ERBB2 and is a member of the HER family. Unlike other members of the HER family, HER2 does not contain sites and signals that bind to other heterodimer ligands [27]. In gastric cancer, 7%-4% of tumors were found to have ERBB2 ampli cation or HER2 overexpression.…”